Efficacy, Safety, and Tolerability of Long-Term Combination Antiretroviral Therapy in Asymptomatic Treatment-Naïve Adults with Early HIV Infection

REFERENCES

• Dybul M, Fauci AS, Bartlett JG, Kaplan JE, Pau AK. Guide-lines for using antiretroviral agents among HIV-infected adults and adolescents. Recommendations of the Panel on Clinical Practices for Treatment of HIV. MMWR Recomm Rep. 2002 51:1-55. Available at: http://www.hivatis.org.
   PubMedGoogle Scholar
• Freedberg KA, Losina E, Weinstein MC, et al. The cost effectiveness of combination antiretroviral therapy for HIV disease. N Enql J Med. 2001344: 824–831.
   Google Scholar
• Gulick RM, Mellors JW, Havlir D, et al. Treatment with in-dinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N Enql J Med. 1997;337:734–739.
   PubMed Web of Science ®Google Scholar
• Hammer SM, Squires KE, Hughes MD, et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Tri-als Group 320 Study Team. N Engl J Med. 1997;337:725–733.
   PubMed Web of Science ®Google Scholar
• Hogg RS, Heath KV, Yip B, et al. Improved survival among HIV-infected individuals following initiation of antiretroviral therapy. JAMA. 1998;279:450–454.
   PubMed Web of Science ®Google Scholar
• Li TS, Tubiana R, Katlama C, Calvez V, Ait MH, Autran B. Long-lasting recovery in CD4 T-cell function and viral-load reduction after highly active antiretroviral therapy in ad-vanced HIV-1 disease. Lancet. 1998;351:1682–1686.
   PubMed Web of Science ®Google Scholar
• Mocroft A, Vella S, Benfield TL, et al. Changing patterns of mortality across Europe in patients infected with HIV-1. EuroSIDA Study Group. Lancet 1998;352:1725–1730.
   PubMed Web of Science ®Google Scholar
• Palella FJ Jr, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Enql J Med. 1998;338:853–860.
   Google Scholar
• Vittinghoff E, Scheer S, O'Malley P, Colfax G, Holmberg SD, Buchbinder SP. Combination antiretroviral therapy and recent declines in AIDS incidence and mortality. J Infect Dis. 1999;179:717–720.
   Google Scholar
• Gulick RM, Mellors JW, Havlir D, et al. 3-year suppression of HIV viremia with indinavir, zidovudine, and lamivudine. Ann Intern Med. 2000;133: 35–39.
   PubMed Web of Science ®Google Scholar
• Gulick RM, Meibohm A, Havlir D, et al. Six-year follow-up of HIV-1-infected adults in a clinical trial of antiretroviral therapy with indinavir, zidovudine, and lamivudine. AIDS. 2003;17:2345–2349.
   PubMed Web of Science ®Google Scholar
• Giorgi JV, Lyles RH, Matud JL, et al. Predictive value of immunologic and virologic markers after long or short du-ration of HIV-1 infection. J Acquir Immune Defic Syndr. 2002;29:346–355.
   PubMed Web of Science ®Google Scholar
• Opravil M, Ledergerber B, Furrer H, et al. Clinical efficacy of early initiation of HAART in patients with asymptomatic HIV infection and CD4 cell count > 350 x 106 /I. AIDS. 2002;16:1371–1381.
   PubMed Web of Science ®Google Scholar
• Schackman BR, Freedberg KA, Weinstein MC, et al. Cost-effectiveness implications of the timing of antiret-roviral therapy in HIV-infected adults. Arch Intern Med. 2002;162:2478–2486.
   PubMed Web of Science ®Google Scholar
• Di Mascio M, Markowitz M, Louie M, et al. Viral blip dy-namics during highly active antiretroviral therapy. J ViroL 2003;77:12165–12172.
   PubMed Web of Science ®Google Scholar
• Di Mascio M, Ribeiro RM, Markowitz M, Ho DD, Perelson AS. Modeling the long-term control of viremia in HIV-1 infected patients treated with antiretroviral therapy. Math Biosci. 2004;188: 47–62.
   PubMed Web of Science ®Google Scholar
• Havlir DV, Bassett R, Levitan D, et al. Prevalence and pre-dictive value of intermittent viremia with combination HIV therapy. JAMA. 2001286: 171–179.
   Google Scholar
• Pillay D. HIV viral load: the myth of the undetectable? Rev Med Virol. 2002;12:391–396.
   Google Scholar
• Sklar PA, Ward DJ, Baker RK, et al. Prevalence and clinical correlates of HIV viremia ("blips") in patients with previ-ous suppression below the limits of quantification. AIDS. 2002;16:2035–2041.
   PubMed Web of Science ®Google Scholar
• Sungkanuparph S, Overton ET, Seyfried W, Groger RK, Fraser VJ, Powderly WG. Intermittent episodes of de-tectable HIV viremia in patients receiving nonnucleoside reverse-transcriptase inhibitor-based or protease inhibi-tor-based highly active antiretroviral therapy regimens are equivalent in incidence and prognosis. Clin Infect Dis. 2005;41:1326–1332.
   PubMed Web of Science ®Google Scholar
• Di Mascio M, Markowitz M, Louie M, et al. Dynamics of in-termittent viremia during highly active antiretroviral therapy in patients who initiate therapy during chronic versus acute and early human immunodeficiency virus type 1 infection. J Virol. 2004;78:10566–10573.
   PubMed Web of Science ®Google Scholar
• Di Mascio M, Percus JK, Percus OE, Markowitz M, Ho DD, Perelson AS. Duration of an intermittent episode of viremia. Bull Math Biol. 2005;67:885–900.
   PubMed Web of Science ®Google Scholar
• Havlir DV, Hellmann NS, Petropoulos CJ, et al. Drug sus-ceptibility in HIV infection after viral rebound in patients receiving indinavir-containing regimens. JAMA. 2000;283: 229–234.
   PubMed Web of Science ®Google Scholar
• Hermankova M, Ray SC, Ruff C, et al. HIV-1 drug re-sistance profiles in children and adults with viral load of <50 copies/ml receiving combination therapy. JAMA. 2001286: 196–207.
   Google Scholar
• Karlsson AC, Younger SR, Martin JN, et al. Immunologic and virologic evolution during periods of intermittent and persistent low-level viremia. AIDS. 2004;18:981–989.
   PubMed Web of Science ®Google Scholar
• Macias J, Palomares JC, Mira JA, et al. Transient rebounds of HIV plasma viremia are associated with the emergence of drug resistance mutations in patients on highly active antiretroviral therapy. J Infect. 2005;51:195–200.
   PubMed Web of Science ®Google Scholar
• Mira JA, Macias J, Nogales C, et al. Transient rebounds of low-level viraemia among HIV-infected patients under HAART are not associated with virological or immunologi-cal failure. Antivir Ther. 2002;7:251–256.
   PubMed Web of Science ®Google Scholar
• Papasawas E, Kostman JR, Thiel B, et al. HIV-1-specific CD4+ T cell responses in chronically HIV-1 infected blippers on antiretroviral therapy in relation to viral replication following treatment interruption. J Clin ImmunoL 2006; 26:40–54.
   PubMed Web of Science ®Google Scholar
• Percus JK, Percus OE, Markowitz M, Ho DD, Di Mascio M, Perelson AS. The distribution of viral blips observed in HIV-1 infected patients treated with combination antiretroviral therapy. Bull Math BioL 2003;65:263–277.
   PubMed Web of Science ®Google Scholar
• Raboud JM, Rae S, Woods R, Harris M, Montaner JS. Con-secutive rebounds in plasma viral load are associated with virological failure at 52 weeks among HIV-infected patients. AIDS. 2002;16: 1627–1632.
   PubMed Web of Science ®Google Scholar
• Kimura T, Yoshimura K, Nishihara K, et al. Reconstitution of spontaneous neutralizing antibody response against autologous human immunodeficiency virus during highly active antiretroviral therapy. J Infect Dis. 2002;185:53–60.
   PubMed Web of Science ®Google Scholar
• Miller LG, Golin CE, Liu H, et al. No evidence of an asso-ciation between transient HIV viremia ("blips") and lower adherence to the antiretroviral medication regimen. J Infect Dis. 2004;189:1487–1496.
   PubMed Web of Science ®Google Scholar
• Nettles RE, Kieffer TL, Kwon P, et al. Intermittent HIV-1 viremia (blips) and drug resistance in patients receiving HAART. JAMA. 2005;293:817–829.
   PubMed Web of Science ®Google Scholar
• Sun R, Ku J, Jayakar H, et al. Ultrasensitive reverse tran-scription-PCR assay for quantitation of human immuno-deficiency virus type 1 RNA in plasma. J Clin MicrobioL 1998;36:2964–2969.
   PubMed Web of Science ®Google Scholar
• Kleinman KP, Ibrahim JG, Laird NM. A Bayesian framework for intent-to-treat analysis with missing data. Biometrics. 1998;54:265–278.
   Google Scholar
• Little R, Yau L. Intent-to-treat analysis for longitudinal stud-ies with drop-outs. Biometrics. 1996;52:1324–1333.
   PubMed Web of Science ®Google Scholar
• Tsiatis A. Methodological issues in AIDS clinical trials. In-tent-to-treat analysis. J Acquir Immune Defic Syndr 1990; 3\(suppl 2):S120–5123.
   PubMed Web of Science ®Google Scholar
• Hirsch MS, Steigbigel RT, Staszewski S, et al. Long-term efficacy, safety, and tolerability of indinavir-based therapy in protease inhibitor-naive adults with advanced HIV infec-tion. Clin Infect Dis. 2003;37:1119–1124.
   PubMed Web of Science ®Google Scholar
• Haas DW, Arathoon E, Thompson MA, et al. Comparative studies of two-times-daily versus three-times-daily indina-vir in combination with zidovudine and lamivudine. AIDS. 2000;14:1973–1978.
   PubMed Web of Science ®Google Scholar
• Carr A, Chuah J, Hudson J, et al. A randomised, open-la-bel comparison of three highly active antiretroviral therapy regimens including two nucleoside analogues and indinavir for previously untreated HIV-1 infection: the OzCombo1 study. AIDS. 2000;14:1171–1180.
   PubMed Web of Science ®Google Scholar
• Bonfanti P, Valsecchi L, Parazzini F, et al. Incidence of adverse reactions in HIV patients treated with protease inhibitors: a cohort study. JAIDS. 2000;23:236–245.
   Google Scholar
• Duval X, Journot V, Leport C, et al. Incidence of and risk factors for adverse drug reactions in a prospective cohort of HIV-infected adults initiating protease inhibitor-contain-ing therapy. Clin Infect Dis. 2004;39:248–255.
   PubMed Web of Science ®Google Scholar
• Finzi D, Hermankova M, Pierson T, et al. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science. 1997;278:1295–1300.
   PubMed Web of Science ®Google Scholar
• Ho DD. Time to hit HIV, early and hard. N Engl J Med. 1995;333:450–451.
   PubMed Web of Science ®Google Scholar
• Ho DD. Toward HIV eradication or remission: the tasks ahead. Science. 1998;280:1866–1867.
   PubMed Web of Science ®Google Scholar
• Koup RA, Ho DD. Shutting down HIV. Nature. 1994; 370:416.
   PubMed Web of Science ®Google Scholar
• Mittler JE, Markowitz M, Ho DD, Perelson AS. Improved estimates for HIV-1 clearance rate and intracellular delay. AIDS. 1999;13:1415–1417.
   PubMed Web of Science ®Google Scholar
• Perelson AS, Essunger P, Cao Y, et al. Decay characteris-tics of HIV-1-infected compartments during combination therapy. Nature. 1997;387:188–191.
   PubMed Web of Science ®Google Scholar
• Ramratnam B, Mittler JE, Zhang L, et al. The decay of the latent reservoir of replication-competent HIV-1 is inversely correlated with the extent of residual viral replication during prolonged anti-retroviral therapy. Nat Med. 2000;6:82–85.
   PubMed Web of Science ®Google Scholar
• Simon V, Ho DD. HIV-1 dynamics in vivo: implications for therapy. Nat Rev MicrobioL 2003;1:181–190.
   PubMed Web of Science ®Google Scholar
• Zhang L, Ramratnam B, Tenner-Racz K, et al. Quantifying residual HIV-1 replication in patients receiving combination antiretroviral therapy. N Engl J Med. 1999;340: 1605–1613.
   PubMed Web of Science ®Google Scholar
• Clerici M, Seminari E, Maggiolo F, et al. Early and late effects of highly active antiretroviral therapy: a 2 year fol-low-up of antiviral-treated and antiviral-naive chronically HIV-infected patients. AIDS. 2002;16:1767–1773.
   PubMed Web of Science ®Google Scholar
• Mauskopf J, Kitahata M, Kauf T, Richter A, Tolson J. HIV antiretroviral treatment: early versus later. J Acquir Immune Defic Syndr 2005;39: 562–569.
   PubMed Web of Science ®Google Scholar
• Thorner A, Rosenberg E. Early versus delayed antiretroviral therapy in patients with HIV infection: a review of the cur-rent guidelines from an immunological perspective. Drugs. 2003;63:1325–1337.
   PubMed Web of Science ®Google Scholar
• Lehrman G, Hogue IB, Palmer S, et al. Depletion of latent HIV infection in vivo: a proof-of-concept study. Lancet. 2005; 366:549–555.
   PubMed Web of Science ®Google Scholar
• Chun TW, Justement JS, Moir S, et al. Decay of the HIV reservoir in patients receiving of antiretroviral therapy for extended periods: implications for eradication of virus. J Infect Dis. 2007;195:1762–1764.
   PubMed Web of Science ®Google Scholar